Clinical trial
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa…
NCT00386425 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00386425 |
|---|---|
| Title | Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated) |
| Official title | A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients With Severe Sepsis and Multiple Organ Dysfunction |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Severe Sepsis |
| Intervention type | Drug |
| Interventions | Drotrecogin alfa (activated) |
| Enrollment | 486 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Oct 11, 2006 |
| Last update posted | Dec 16, 2010 |
| Countries | Belgium, Canada, Finland, France, Germany, Puerto Rico, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: